Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Vail

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
Journal of Veterinary Internal Medicine|June 5, 2026
Efficacy and safety evaluation of gilvetmab in dogs with melanoma and mast cell tumorEsther Chon, Mohamad Morsey, Terry Katz, et al.
BMC Veterinary Research|June 12, 2015
Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcomaHeather L Gardner, Cheryl A London, Roberta A Portela, et al.
Melanoma Research|May 20, 2024
Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanomaMark R Albertini, Cindy L Zuleger, Erik A Ranheim, et al.
Frontiers in Immunology|May 30, 2025
Single cell atlas of canine natural killer cells identifies distinct circulating and tissue resident gene profilesAryana M Razmara, Marshall Lammers, Sean J Judge, et al.
Frontiers in Immunology|November 10, 2025
Comparative transcriptomic analysis of tumor- infiltrating canine natural killer cells and candidate biomarkers from first-in-dog NK immunotherapy trialsAryana M Razmara, Marshall Lammers, Sean J Judge, et al.
Journal of the American Veterinary Medical Association|November 23, 2024
Low prevalence of occult cancer diagnosis when screening healthy, higher-risk, middle-aged to older dogsJenna H Burton, David M Vail, Jennifer L Willcox, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2009
Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphomaDavid M Vail, Douglas H Thamm, Hans Reiser, et al.
Plos One|August 12, 2021
Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) settingKara Magee, Ian R Marsh, Michelle M Turek, et al.
Molecular Cancer Therapeutics|July 25, 2022
Comparative Oncology Assessment of a Novel Inhibitor of Valosin-Containing Protein in Tumor-Bearing DogsAmy K LeBlanc, Christina N Mazcko, Timothy M Fan, et al.
Science Translational Medicine|February 5, 2016
Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative OncologyAmy K LeBlanc, Matthew Breen, Peter Choyke, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Journal of Veterinary Internal Medicine|June 5, 2026
Efficacy and safety evaluation of gilvetmab in dogs with melanoma and mast cell tumorEsther Chon, Mohamad Morsey, Terry Katz, et al.
BMC Veterinary Research|June 12, 2015
Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcomaHeather L Gardner, Cheryl A London, Roberta A Portela, et al.
Melanoma Research|May 20, 2024
Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanomaMark R Albertini, Cindy L Zuleger, Erik A Ranheim, et al.
Frontiers in Immunology|May 30, 2025
Single cell atlas of canine natural killer cells identifies distinct circulating and tissue resident gene profilesAryana M Razmara, Marshall Lammers, Sean J Judge, et al.
Frontiers in Immunology|November 10, 2025
Comparative transcriptomic analysis of tumor- infiltrating canine natural killer cells and candidate biomarkers from first-in-dog NK immunotherapy trialsAryana M Razmara, Marshall Lammers, Sean J Judge, et al.
Journal of the American Veterinary Medical Association|November 23, 2024
Low prevalence of occult cancer diagnosis when screening healthy, higher-risk, middle-aged to older dogsJenna H Burton, David M Vail, Jennifer L Willcox, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2009
Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphomaDavid M Vail, Douglas H Thamm, Hans Reiser, et al.
Plos One|August 12, 2021
Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) settingKara Magee, Ian R Marsh, Michelle M Turek, et al.
Molecular Cancer Therapeutics|July 25, 2022
Comparative Oncology Assessment of a Novel Inhibitor of Valosin-Containing Protein in Tumor-Bearing DogsAmy K LeBlanc, Christina N Mazcko, Timothy M Fan, et al.
Science Translational Medicine|February 5, 2016
Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative OncologyAmy K LeBlanc, Matthew Breen, Peter Choyke, et al.
Pageof 8